Grigoris Gerotziafas
Visiitng Professor, Hematology
22559410
School of Medicine
Visiting Professor
Academic Qualifications
| Qualification | Year | Awarding Institution | Department | Thesis title (Optional Entry) |
| University degree of Medical Doctor | 1991 | Aristotle University of Thessaloniki, Greece. | Faculty of Medicine | |
| Diplôme d’Études Approfondies (equivalent to Master 2) in Pathogenesis of Thrombosis | 1994 | University Pierre et Marie Curie,France | Faculty of Medicine Broussais Hotel-Dieu | |
| PhD degree on Cardiovascular Pharmacology | 1999 | University Pierre et Marie Curie,Paris VI, France | Faculty of Medicine | "Génération du FVIIa pendant la coagulation du plasma humain. Etude du mécanisme d’inhibition de la génération et de l’activité du FVIIa induite par le pentasaccharide synthétique, l’héparine de bas poids moléculaire et l’héparine non fractionnée. Comparaison avec l’hirudine recombinante" |
| Postdoctoral- Laboratory of Biochemistry | 1999-2002 | University of Thessaloniki, Greece. | Faculty of Chemisty | |
| Qualification as specialist in Hematology | 2002 | Greek and European Union Health Authorities | ||
| Habilitation à Diriger la Recherche | 2016 | University Pierre et Marie Curie (Paris VI) | Faculty of Medicine |
Employment History
| Period of employment | Employer | Location | Position | |
| From | To | |||
| 01/06/2002 | 31/12/2002 | Department of Emergency, University Hospital Hotel-Dieu | Paris, France | Assistance Publique Hopitaux de Paris |
| 26/9/2003 | 30/9/2005 | Department of Haemostasis, Hospital Robert Debrι | Paris, France | |
| 1/11/2005 | 31/08/2008 | Department of Haemostasis, University Hospital Tenon, University Pierre et Marie Curie | Paris, France | |
| 01/09/2008 | Ongoing | University Hτpital Tenon, Assistance Publique Hτpitaux de Paris, University Pierre et Marie Curie, Paris VI. | Paris, France | |
Publications
| Year | Title | Other authors | Journal and Publisher / Conference | Vol. | Pages |
| 2018 | Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation | Chaussade E, Hanon O, Boully C, Labourιe F, Caillard L, Gerotziafas G, Vidal JS, Elalamy I. | J Nutr Health Aging | 22 | 165-173 |
| 2018 | Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation | Chaussade E, Hanon O, Boully C, Labourιe F, Caillard L, Gerotziafas G, Vidal JS, Elalamy I. | J Nutr Health Aging | 22 | 165-173 |
| 2013 | Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma. | Papageorgiou C, Vandreden P, Marret E, Bonnet F, Robert F, Spyropoulos A, Galea V, Elalamy I, Hatmi M, Gerotziafas GT. | Thromb Res | 132 | 584-91. |
| 2012 | The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles | Gerotziafas GT, Van Dreden P, Chaari M, Galea V, Khaterchi A, Lionnet F, Stankovic-Stojanovic K, Blanc-Brude O, Woodhams B, Maier-Redelsperger M, Girot R, Hatmi M, Elalamy I. | Thromb Haemost | 107 | 1044-52 |
| 2017 | Gavaises M.Modelling of thrombin generation under flow in realistic left anterior descending geometries | Papadopoulos KP, Gerotziafas GT | Med Eng Phys | 50 | 50-58 |
| 2017 | Impact of blood hypercoagulability on in vitro fertilization outcomes: a prospective longitudinal observational study | Gerotziafas GT, Van Dreden P, Mathieu d'Argent E, Lefkou E, Grusse M, Comtet M, Sangare R,Ketatni H, Larsen AK, Elalamy I | Thromb J. | 15 | 9 |
| 2016 | Rapid detection of D-Dimers with mLabs® whole blood method for venous thromboembolism exclusion. Comparison with Vidas® D-Dimers assay | Gerotziafas GT, Ray P, Gkalea V, Benzarti A, Khaterchi A, Cast C, Pernet J, Lefkou E, Elalamy I | Int Angiol. | 35 | 622-628 |
| 2007 | Prophylaxis for venous thrombosis in medical and surgical patients. Womens’ vascular health | Gerotziafas GT, Samama MM. | Hodder Arnold. Editι par Greer I, Ginsberg J, Forbes CD. | 171-185. | |
| 2017 | Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer. | Rousseau A, Van Dreden P,Khaterchi A, Larsen AK, Elalamy I, Gerotziafas GT. | Int J Oncol. | 51 | 1793-1800 |
| 2015 | Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin, | Rousseau A, Van Dreden P, Mbemba E, Elalamy I, Larsen A, Gerotziafas GT | Thromb Res | 136 | 1273-9 |
| 1998 | Comparative effects of synthetic pentasaccharide, low molecular weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. | Gerotziafas GT, Bara L, Bloch MF, Makris PE, Samama MM. | Blood Coagul Fibrinolysis | 9 | 571-580. |
Exhibitions
Research Projects
| Title | Funded by | Project Role* |
| Modelisation of the interaction of cells from solid cancers or haematological malignancies with the vascular and haemostatic components of the microenvironment and related alterations in the activity of antithrombotic and anticancer agents. | Principal Investigator and Academic Supervisor | |
| Modelisation of the link between vascular mimicry properties of cancer cells and modulation of blood coagulation. | Principal Investigator and Academic Supervisor | |
| Pharmacological and functional characterization of heparins and glycosaminoglycan derivatives | Principal Investigator and Academic Supervisor | |
| Development of clinico-biological risk assessment models for the identification of patients with solid cancers or haematological malignancies at risk of cancer associated thrombosis. | Translational research | |
| Clinical trials on the prevention of cancer associated thrombosis | Translational research | |
| Development of diagnostic strategies for the biological monitoring of treatment treatment with direct orally active anticoagulants | Translational research | |
| ROADMAP-IVF: Prospective risk assessment and biomarkers of hypercoagulability for the identification of women eligible for in vitro fertilization at risk of negative pregnancy outcome. International observational study in collaboration with Dr. E Mathieu and Pr. N. Buffet, Service de Gynecologie Hτpital Tenon, Paris, France et Pr. Tarlatzis, Department of Gynecology Papageorgiou Hospital Thessaloniki Greece. | International, multicenter clinical studies | |
| ATICKS study: AntiThrombotics' Impact on Clot formation Kinetics and Structure. Clinicobiological study. Evaluation of the effect of direct orally active anticoagulants and low molecular weight heparins on thrombin generation and clot formation kinetics and physical characteristics. | International, multicenter clinical studies | |
| PRONIA-CAT: Thromboprophylaxis of Metastatic cancer patients with the low molecular weight heparin tinzaparin. Long term prevention of venous thromboembolism with low dose tinzaparin in patients with breast or prostate cancer at high risk for cancer associated thrombosis. A prospective, randomized, international multicenter, placebo controlled, open-label, blinded-endpoint study. A Phase III investigator initiated study on 1400 patients. Patients' recruitment will start in the first trimester of 2018. | International, multicenter clinical studies | |
| COMPASS-CAT: Prospective multicenter international observational study for derivation of a new risk assessment model for cancer associated thrombosis in ambulatory patients on chemotherapy for breast, colorectal, lung, or ovarian Cancer. This project has been organized in collaboration with experts of Middle East, Greece, France, USA, has already given une publication (The Oncologist 2017) and is continued with the elaboration of strategies for implementation of the predictive tools and guidelines for prevention of cancer associated thrombosis in real life clinical practice. | International, multicenter clinical studies | |
| HeparinFuture: Pharmacological analysis and identification of the anticoagulant properties of heparin dérivatives and biosimilars. Project in collaboration with the Department of Pathology and Pharmacology, Stritch School of Medicine, Loyola University, Chicago USA (Prof J Fareed et Prof J Walega). | International, multicenter clinical studies |
Academic Consulting Services/Councils/Boards/Editorial Committees
| Organization | Title of Position or Service | Key Activities |
| Faculty de Medicine, University Pierre et Marie Curie, Paris VI. | Theoretical courses and practical seminars on Haemostasis and Thrombosis to the students of the | Teaching |
| Faculty de Medicine, University Pierre et Marie Curie, Paris VI. | Theoretical courses and practical seminars on Haemostasis and Thrombosis to the students of the | Teaching |
| International Union of Angiology | Member of the administration board of VAS – Vascular Independent Research and Education European Foundation, endorsed | Appointments as an expert in the field of thrombosis and haemostasis |
| Member of the Editorial Board of the International Conference on Thrombosis and Hemostasis Issues in Cancer Magazine | ||
| Member of the administration board of VAS – Vascular Independent Research and Education European Foundation, endorsed by the International Union of Angiology | ||
| Chairman of the national Hellenic committee for the therapeutic protocols for the prevention and treatment of venous thromboembolic disease, endorsed by the Greek Ministry of Health. |
Awards/International Recognition
| Date | Title |
| 2000 | International Society of Thrombosis |
| STAGO Award for innovative research in Thrombosis and Haemostasis | |
| 2008 | Haemostasis young investigator award |
| 2017,2018 | ISTH award for best poster presentation |